[1] 王秀, 刘真, 吴晶晶, 等. 人附睾蛋白4、CA199、LPA在卵巢癌中的表达及与临床病理特征的相关性[J]. 蚌埠医学院学报, 2021, 46(2): 183.
[2] STRATTON MR, CAMPBELL PJ, FUTREAL PA. The cancer genome[J]. Nature, 2009, 458(7239): 719. doi: 10.1038/nature07943
[3] STRATTON MR. Exploring the genomes of cancer cells: progress and promise[J]. Science, 2011, 331(6024): 1553. doi: 10.1126/science.1204040
[4] MATSUMOTO K, NISHIMURA M, ONOE T, et al. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy[J]. Jpn J Clin Oncol, 2019, 49(8): 703. doi: 10.1093/jjco/hyz090
[5] JIANG X, LI X, LI W, et al. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms[J]. J Cell Mol Med, 2019, 23(4): 2303. doi: 10.1111/jcmm.14133
[6] MADARIAGA A, LHEUREUX S, OZA AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations[J]. Cancers (Basel), 2019, 11(3): 416. doi: 10.3390/cancers11030416
[7] 饶阳, 李潇, 徐德欢, 等. 74例上皮性卵巢癌患者BRCA基因突变状况及临床意义分析[J]. 国际妇产科杂志, 2021, 48(3): 351.
[8] KORKMAZ T, SEBER S, BASARAN G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials[J]. Crit Rev Oncol Hematol, 2016, 98: 180. doi: 10.1016/j.critrevonc.2015.10.006
[9] SUSANNA LC, JAMES DB. Evolution of platinum resistance in high-grade serous ovarian cancer. [J]. Lancet Oncol, 2011, 12(12): 1169. doi: 10.1016/S1470-2045(11)70123-1
[10] 中国抗癌协会妇科肿瘤专业委员会. 中国卵巢上皮性癌维持治疗专家共识(2019)[J]. 中国实用妇科与产科杂志, 2019, 35(6): 655.
[11] GONZALO HG. Management of relapsed ovarian cancer: a review[J]. Springerplus, 2016, 5(1): 1197. doi: 10.1186/s40064-016-2660-0
[12] SAIRA K, JANE MH, JONATHAN AL, et al. Maintenance therapy in ovarian cancer[J]. Curr Opin Oncol, 2014, 26(5): 521. doi: 10.1097/CCO.0000000000000110
[13] 高庆蕾, 孔北华, 尹如铁, 等. PARP抑制剂治疗复发性卵巢癌专家共识[J]. 现代妇产科进展, 2018, 27(10): 721.
[14] KATHLEEN M, NICOLETTA C, GIOVANNI S, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2018, 379(26): 2495. doi: 10.1056/NEJMoa1810858
[15] ERIC PL, JONATHAN AL, FREDERIC S, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9): 1274. doi: 10.1016/S1470-2045(17)30469-2
[16] ROY R, CHUN J, POWELL SN. BRCA1 and BRCA2: different roles in a common pathway of genome proctection[J]. Nat Rev Cancer, 2011, 12(1): 68
[17] HALL MJ, REID JE, BURBIDGE LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer[J]. Cancer, 2009, 115(10): 2222. doi: 10.1002/cncr.24200
[18] ELISABETE W, JERZY ET. Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation[J]. Mol Diagn Ther, 2015, 19(6): 351. doi: 10.1007/s40291-015-0168-x
[19] YOU Y, LI L, LU J, et al. Germline and somatic BRCA1/2 mutations in 172 Chinese women with epithelial ovarian Cancer[J]. Front Oncol, 2020, 10: 295. doi: 10.3389/fonc.2020.00295
[20] PENNINGTON KP, WALSH T, HARREL MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas[J]. Clin Cancer Res, 2014, 20(3): 764.